Evaluation of a topically administered carbonic anhydrase inhibitor (MK-927) in normotensive and glaucomatous Beagles

SUMMARY A new topically administered anhydrase inhibitor, MK-927, was evaluated for its ocular hypotensive activity in normotensive and glaucomatous Beagles. Single- and multiple-dose studies were performed. Six concentrations of the drug were evaluated in the single-dose study and the 2% solution was used for multiple-dose evaluation. The decrease in intraocular pressure (iop) was greater in glaucomatous Beagles at the higher concentrations of the drug. The 2 and 4% solutions of MK-927 significantly lowered iop (mean, 5 mm of Hg; sem ± 1.6 and sem ± 1.2, respectively) in normotensive and glaucomatous Beagles. In the multiple-dose study, iop was significantly decreased in the normotensive (mean, 4 mm of Hg; sem ± 0.74) and glaucomatous Beagles (mean, 9 mm of Hg; sem ± 1.2). The maximal effect was observed by day 4. A contralateral effect was found in glaucomatous Beagles, with the maximal effect on day 4.